{
    "medicine_id": "f68abfe31a98d1349c8ef22ebc23655164035772",
    "platform_id": "DB12442",
    "metadata": {
        "name": "Byfavo 2 5 mg 1mL Injection powder lyophilized for solution",
        "composition": "2 5 mg 1mL Alvespimycin",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use as an antineoplastic agent for solid tumors advanced solid tumours or acute myeloid leukaemia",
            "contraindications": {
                "disease": "Alvespimycin exhibits a dose limiting toxicity where most toxic effects were experienced at 80mg m 2 in Phase I clinical trials Common adverse effects include nausea vomiting fatigue hematologic toxicity liver enzyme disturbances and ocular disturbances including blurred vision and keratitis They are reported to be generally reversible The doses lower than 80mg m 2 are well tolerated The dose limiting",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Alvespimycin mediates an antitumor activity through HSP90 inhibition that targets client proteins for proteasomal destruction including oncogenic kinases such as BRAF The administration of the drug is shown to result in the depletion of client proteins that have oncogenic activity and potential induction of HSP70 HSP72 A19243 It is more selective for tumors over normal tissue A study also reports that alvespimycin enhances the potency of telomerase inhibition by imetelstat in pre clinical models of human osteosarcoma A19245",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}